- We will send in 10–14 business days.
/images/books/11785052/9781680838206.jpg)
- Author: Robert S Danziger
- Publisher: Now Publishers
- ISBN-10: 1680838202
- ISBN-13: 9781680838206
- Format: 15.6 x 23.4 x 0.6 cm, minkšti viršeliai
- Language: English
- SAVE -10% with code: EXTRA
Government Royalties on Sales of Pharmaceutical and Other Biomedical Products Developed with Substantial Public Funding (e-book) (used book) | bookbook.eu
Reviews
Description
This study develops a detailed description of the successful technology transfer of an invention -- the drug-eluting coronary stent -- originating in intramural research within the US National Institutes of Health. The history of the commercialization of the invention is used to illustrate a new policy, proposed and explained in this study, for the payment to the government of royalties on the sales of biomedical products developed with substantial public funding provided through indirect as well as direct funding avenues. The proposed policy addresses concerns about the high prices that taxpayers as consumers pay for biomedical products that were developed with funding from the taxpayers as investors. The study explains the theoretical circumstances in which the policy would not adversely affect the appropriate level of R&D investment, and then uses the history of the drug-eluting coronary stent as an example where biomedical R&D is consistent with those circumstances.
EXTRA 10 % discount with code: EXTRA
The promotion ends in 22d.17:01:41
The discount code is valid when purchasing from 10 €. Discounts do not stack.
- Author: Robert S Danziger
- Publisher: Now Publishers
- ISBN-10: 1680838202
- ISBN-13: 9781680838206
- Format: 15.6 x 23.4 x 0.6 cm, minkšti viršeliai
- Language: English English
This study develops a detailed description of the successful technology transfer of an invention -- the drug-eluting coronary stent -- originating in intramural research within the US National Institutes of Health. The history of the commercialization of the invention is used to illustrate a new policy, proposed and explained in this study, for the payment to the government of royalties on the sales of biomedical products developed with substantial public funding provided through indirect as well as direct funding avenues. The proposed policy addresses concerns about the high prices that taxpayers as consumers pay for biomedical products that were developed with funding from the taxpayers as investors. The study explains the theoretical circumstances in which the policy would not adversely affect the appropriate level of R&D investment, and then uses the history of the drug-eluting coronary stent as an example where biomedical R&D is consistent with those circumstances.
Reviews